Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
Hepatol Int ; 2024 Jun 04.
Article in English | MEDLINE | ID: mdl-38833138

ABSTRACT

BACKGROUND: To provide patients the chance of accepting curative transjugular intrahepatic portosystemic shunt (TIPS) rather than palliative treatments for portal hypertension-related variceal bleeding and ascites, we aimed to assess hepatic-associated vascular morphological change to improve the predictive accuracy of overt hepatic encephalopathy (HE) risks. METHODS: In this multicenter study, 621 patients undergoing TIPS were subdivided into training (413 cases from 3 hospitals) and external validation datasets (208 cases from another 3 hospitals). In addition to traditional clinical factors, we assessed hepatic-associated vascular morphological changes using maximum diameter (including absolute and ratio values). Three predictive models (clinical, hepatic-associated vascular, and combined) were constructed using logistic regression. Their discrimination and calibration were compared to test the necessity of hepatic-associated vascular assessment and identify the optimal model. Furthermore, to verify the improved performance of ModelC-V, we compared it with four previous models, both in discrimination and calibration. RESULTS: The combined model outperformed the clinical and hepatic-associated vascular models (training: 0.814, 0.754, 0.727; validation: 0.781, 0.679, 0.776; p < 0.050) and had the best calibration. Compared to previous models, ModelC-V showed superior performance in discrimination. The high-, middle-, and low-risk populations displayed significantly different overt HE incidence (p < 0.001). Despite the limited ability of pre-TIPS ammonia to predict overt HE risks, the combined model displayed a satisfactory ability to predict overt HE risks, both in the low- and high-ammonia subgroups. CONCLUSION: Hepatic-associated vascular assessment improved the predictive accuracy of overt HE, ensuring curative chances by TIPS for suitable patients and providing insights for cirrhosis-related studies.

2.
Environ Sci Process Impacts ; 26(6): 1022-1030, 2024 Jun 19.
Article in English | MEDLINE | ID: mdl-38747329

ABSTRACT

The accumulation of petroleum contaminants in phytoremediating plants can significantly impact the decomposition of their litter. However, the mechanisms underlying these effects and the potential influence of the contaminant concentration remain unclear. In this study, litter from Artemisia annua plants grown in soil with varying concentrations of petroleum (0, 15, 30, and 45 g kg-1) was collected. The litter samples were then inoculated with soil microorganisms and subjected to an indoor simulation of decomposition under controlled temperature and humidity conditions. Changes in the chemical properties, activities of decomposition-related enzymes in the litter, and decomposition rates were measured. Additionally, structural equation modeling was employed to analyze the mechanism through which soil petroleum contamination affects litter decomposition. The findings revealed several key points: (1) increasing soil petroleum contamination tended to reduce the concentration of carbon and nitrogen in litter while increasing those of lignin and total petroleum hydrocarbons (TPH). (2) Soil petroleum contamination tended to increase the activities of both total lignocellulases and total nutrient cycling-related enzymes in litter. (3) Soil petroleum contamination might indirectly inhibit the activity of lignocellulases by increasing the concentration of lignin and TPH in litter. However, it might also directly accelerate the activity of these enzymes, resulting in contradictory effects on litter decomposition. (4) Finally, A. annua litter produced in soil contaminated with 15 and 30 g kg-1 of petroleum exhibited significantly lower decomposition rates than that from uncontaminated soil.


Subject(s)
Artemisia annua , Biodegradation, Environmental , Petroleum , Soil Microbiology , Soil Pollutants , Artemisia annua/chemistry , Soil Pollutants/analysis , Soil/chemistry , Petroleum Pollution/analysis
3.
Liver Int ; 44(2): 472-482, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38010919

ABSTRACT

BACKGROUND AND AIMS: The transjugular intrahepatic portosystemic shunt has controversial survival benefits; thus, patient screening should be performed preoperatively. In this study, we aimed to develop a model to predict post-transjugular intrahepatic portosystemic shunt mortality to aid clinical decision making. METHODS: A total of 811 patients undergoing transjugular intrahepatic portosystemic shunt from five hospitals were divided into the training and external validation data sets. A modified prediction model of post-transjugular intrahepatic portosystemic shunt mortality (ModelMT ) was built after performing logistic regression. To verify the improved performance of ModelMT , we compared it with seven previous models, both in discrimination and calibration. Furthermore, patients were stratified into low-, medium-, high- and extremely high-risk subgroups. RESULTS: ModelMT demonstrated a satisfying predictive efficiency in both discrimination and calibration, with an area under the curve of .875 in the training set and .852 in the validation set. Compared to previous models (ALBI, BILI-PLT, MELD-Na, MOTS, FIPS, MELD, CLIF-C AD), ModelMT showed superior performance in discrimination by statistical difference in the Delong test, net reclassification improvement and integrated discrimination improvement (all p < .050). Similar results were observed in calibration. Low-, medium-, high- and extremely high-risk groups were defined by scores of ≤160, 160-180, 180-200 and >200, respectively. To facilitate future clinical application, we also built an applet for ModelMT . CONCLUSIONS: We successfully developed a predictive model with improved performance to assist in decision making for transjugular intrahepatic portosystemic shunt according to survival benefits.


Subject(s)
Portasystemic Shunt, Transjugular Intrahepatic , Humans , Retrospective Studies , Liver Cirrhosis/complications , Liver Cirrhosis/surgery , Treatment Outcome
4.
Hepatol Int ; 17(6): 1545-1556, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37531069

ABSTRACT

BACKGROUND: Overt hepatic encephalopathy (HE) should be predicted preoperatively to identify suitable candidates for transjugular intrahepatic portosystemic shunt (TIPS) instead of first-line treatment. This study aimed to construct a 3D assessment-based model to predict post-TIPS overt HE. METHODS: In this multi-center cohort study, 487 patients who underwent TIPS were subdivided into a training dataset (390 cases from three hospitals) and an external validation dataset (97 cases from another two hospitals). Candidate factors included clinical, vascular, and 2D and 3D data. Combining the least absolute shrinkage and operator method, support vector machine, and probability calibration by isotonic regression, we constructed four predictive models: clinical, 2D, 3D, and combined models. Their discrimination and calibration were compared to identify the optimal model, with subgroup analysis performed. RESULTS: The 3D model showed better discrimination than did the 2D model (training: 0.719 vs. 0.691; validation: 0.730 vs. 0.622). The model combining clinical and 3D factors outperformed the clinical and 3D models (training: 0.802 vs. 0.735 vs. 0.719; validation: 0.816 vs. 0.723 vs. 0.730; all p < 0.050). Moreover, the combined model had the best calibration. The performance of the best model was not affected by the total bilirubin level, Child-Pugh score, ammonia level, or the indication for TIPS. CONCLUSION: 3D assessment of the liver and the spleen provided additional information to predict overt HE, improving the chance of TIPS for suitable patients. 3D assessment could also be used in similar studies related to cirrhosis.


Subject(s)
Hepatic Encephalopathy , Portasystemic Shunt, Transjugular Intrahepatic , Humans , Hepatic Encephalopathy/diagnosis , Hepatic Encephalopathy/etiology , Cohort Studies , Spleen , Liver Cirrhosis/complications , Liver Cirrhosis/surgery , Treatment Outcome , Retrospective Studies
5.
Sci Total Environ ; 697: 134189, 2019 Dec 20.
Article in English | MEDLINE | ID: mdl-31491640

ABSTRACT

By altering plant and soil properties and microclimate environments, grazing has a profound influence on the structure and function of grassland ecosystems. However, few studies have addressed the potential grazing effects on snow accumulation and subsequent spring soil water after snow melting and soil thawing. In this study, vegetation properties, snow accumulation and soil water were measured in experimental plots subjected to 8 years of cattle grazing comprising six different grazing intensity treatments in a typical temperate grassland in eastern Eurasia. The results indicated that heavy grazing reduced the snow depth by 51% and the snow mass by 40%. Snow accumulation first rapidly increased but then remained relatively stable with increases in both the aboveground biomass and canopy height. An obvious inflection point occurred at approximately 200 g m-2 aboveground biomass and at a 12.5 cm canopy height. The obvious difference in soil water content between the heavily grazed and ungrazed treatments occurred mainly in the spring after snow melting and soil thawing. The spring soil water content (0-30 cm) reached 31.5% in the ungrazed treatment (G0), which was 1.7 times that in the heavily grazed treatment (G0.92). The soil water content increased exponentially with increasing vegetation properties (aboveground biomass, canopy height and canopy cover), and a similar trend occurred with increasing snow mass and snow depth. Our structural equation modeling showed that both vegetation properties and snow accumulation had significant positive effects on spring soil water. By removing vegetation, grazing at increased intensities had significant, indirect suppressive effects on snow accumulation and spring soil water. Therefore, to obtain increased amounts of snow accumulation and spring soil water, land managers should consider reducing the grazing intensity or leaving some plots ungrazed.


Subject(s)
Grassland , Herbivory , Snow , Animals , Cattle , Environmental Monitoring , Poaceae , Seasons , Soil/chemistry
6.
J Thorac Dis ; 10(6): 3319-3328, 2018 Jun.
Article in English | MEDLINE | ID: mdl-30069328

ABSTRACT

BACKGROUND: The effect of noninvasive ventilation (NIV) in patients with acute respiratory failure (ARF) after cardiac surgery is controversial. This study identified the feasibility of NIV and assessed the risk factors of NIV failure in patients with ARF after cardiac surgery. METHODS: We retrospectively reviewed data from 112 patients with ARF requiring NIV and categorized them into the NIV failure and success groups. Patient data were extracted for further analysis, the primary outcomes were the need for endotracheal intubation and NIV-related in-hospital mortality. The risk factors for NIV failure in patients with post-extubation ARF was analyzed. RESULTS: The median time from extubation to NIV was 11 hours. No difference in the EuroSCORE existed between the two groups. NIV failed in 38.4% of the patients. The NIV failure group had a higher in-hospital mortality and stay at the longer intensive care unit (ICU). Most cases of NIV failure occurred within 1-48 hours of the treatment. The main causes of early NIV failure were a weak cough reflex and/or excessive secretions and hemodynamic instability. A Sequential Organ Failure Assessment (SOFA) score ≥10.5, vasoactive-inotropic score ≥6, and pneumonia were predictors of NIV failure, whereas a body mass index (BMI) ≥25.0 kg/m2 predicted NIV success. CONCLUSIONS: NIV was effective in the study population. Multiple organ dysfunction, pneumonia, and significant inotropic drug support before NIV were associated with NIV failure, whereas a BMI ≥25 kg/m2 was a predictor of NIV success.

7.
Interact Cardiovasc Thorac Surg ; 23(6): 869-975, 2016 12.
Article in English | MEDLINE | ID: mdl-27572613

ABSTRACT

OBJECTIVES: Acute kidney injury requiring renal replacement therapy is an infrequent but dangerous complication of cardiac surgery. Different clinical prediction scores have been developed and validated in American and European countries. Due to the lack of validation in China, the purpose of our study was to validate and compare two clinical scores externally in a Chinese valve surgery population. METHODS: A retrospective analysis was conducted using data obtained from the database of all cardiac valve operations performed during a 5-year period (2010-2014) at a university hospital in Shanghai, China. The primary outcome was defined as the need for renal replacement therapy after cardiac surgery. For evaluation of the scores, discrimination and calibration were measured. RESULTS: After surgery, 52 (1.6%) patients received renal replacement therapy. Patients with different Cleveland scores were found to have significantly different incidences of renal replacement therapy of 0.01, 2.12 and 11.5%. Discrimination of both models was only fair, with values for the area under the receiving operator characteristics curve of 0.68 (95% confidence interval 0.61-0.75) and 0.68 (95% confidence interval 0.61-0.76), respectively. Calibration of the Cleveland score was excellent (P= 0.81) with validity at low score levels; in contrast, calibration of the simplified renal index score was poor (P< 0.001). CONCLUSIONS: Both models provided a certain clinical significance, allowing one to discrimination between patients with higher or lower risks of the postoperative need of renal replacement therapy within the present study population. However, it was not suitable for estimating the real incidence of the need for postoperative renal replacement therapy with sufficient precision in the study sample. Direct clinical use in our centre should be considered cautiously.


Subject(s)
Acute Kidney Injury/etiology , Heart Valves/surgery , Postoperative Complications/etiology , Renal Replacement Therapy , Adult , Aged , China , Female , Humans , Male , Middle Aged , Reproducibility of Results , Retrospective Studies , Risk Assessment
8.
BMC Microbiol ; 13: 273, 2013 Dec 01.
Article in English | MEDLINE | ID: mdl-24289661

ABSTRACT

BACKGROUND: Although a variety of methodologies are available for detection of Salmonella, sensitive, specific, and efficient methods are urgently needed for differentiation of live Salmonella cells from dead cells in food and environmental samples. Propidium monoazide (PMA) can preferentially penetrate the compromised membranes of dead cells and inhibit their DNA amplification, however, such inhibition has been reported to be incomplete by some studies. In the present study, we report an efficient qPCR assay targeting a conserved region of the invA gene of Salmonella in conjunction with PMA treatment for detection of DNA from live Salmonella cells in food samples. RESULTS: We investigated the relationship between amplicon length and inhibitory effect of PMA treatment to prevent DNA amplification from dead cells while allowing for DNA amplification from live cells, and found that the two factors are well correlated with each other. An amplicon that is 130 bp in length was determined to be optimal for PMA treatment and was selected for further PMA-qPCR assay development. A PMA-qPCR assay was established by utilizing this amplicon and adopting a modified PMA-treatment procedure. The PMA-qPCR assay provided excellent inhibition of DNA amplification from dead cells (a 17-CT-value, or 128,000-fold reduction) while only a slight DNA amplification difference (0.5 CT value) was noted between the PMA-treated and untreated live cells. This assay has been validated through stringent inclusivity and exclusivity studies using a large number of (n = 167) Salmonella, including all strains of SARA and SARB collections, and non-Salmonella strains (n = 36). This PMA-qPCR assay is capable of detecting live Salmonella cells in live/dead cell mixtures, or 30 CFU/g live Salmonella cells from enriched spiked spinach samples as early as 4 h. CONCLUSIONS: A 130-bp amplicon in invA gene was demonstrated to be optimal for PMA treatment for selective detection of live Salmonella cells by PCR. This PMA-qPCR assay provides a sensitive, specific, and efficient method for detecting live Salmonella cells in foods and environmental samples and may have an impact on the accurate microbiological monitoring of Salmonella in foods and environment samples.


Subject(s)
Azides/metabolism , Bacteriological Techniques/methods , Enzyme Inhibitors/metabolism , Food Microbiology/methods , Microbial Viability , Propidium/analogs & derivatives , Real-Time Polymerase Chain Reaction/methods , Salmonella/isolation & purification , Bacterial Proteins/genetics , DNA, Bacterial/genetics , Propidium/metabolism , Salmonella/physiology , Sensitivity and Specificity
9.
Biochim Biophys Acta ; 1826(2): 370-84, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22750268

ABSTRACT

A common set of functional characteristics of cancer cells is that cancer cells consume a large amount of glucose, maintain high rate of glycolysis and convert a majority of glucose into lactic acid even in the presence of oxygen compared to that of normal cells (Warburg's Effects). In addition, cancer cells exhibit substantial alterations in several energy metabolism pathways including glucose transport, tricarboxylic acid (TCA) cycle, glutaminolysis, mitochondrial respiratory chain oxidative phosphorylation and pentose phosphate pathway (PPP). In the present work, we focused on reviewing the current knowledge about the dysregulation of the proteins/enzymes involved in the key regulatory steps of glucose transport, glycolysis, TCA cycle and glutaminolysis by several oncogenes including c-Myc and hypoxia inducible factor-1 (HIF-1) and tumor suppressor, p53, in cancer cells. The dysregulation of glucose transport and energy metabolism pathways by oncogenes and lost functions of the tumor suppressors have been implicated as important biomarkers for cancer detection and as valuable targets for the development of new anticancer therapies.


Subject(s)
Citric Acid Cycle , Glucose/metabolism , Glutamine/metabolism , Glycolysis , Neoplasms/metabolism , Oncogenes/physiology , Tumor Suppressor Proteins/physiology , Animals , Biological Transport , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/physiology , Tumor Suppressor Protein p53/physiology
10.
Appl Environ Microbiol ; 78(15): 5297-304, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22635992

ABSTRACT

The goal of this study was to develop a sensitive, specific, and accurate method for the selective detection of viable Escherichia coli O157:H7 cells in foods. A unique open reading frame (ORF), Z3276, was identified as a specific genetic marker for the detection of E. coli O157:H7. We developed a real-time PCR assay with primers and probe targeting ORF Z3276 and confirmed that this assay was sensitive and specific for E. coli O157:H7 strains (n = 298). Using this assay, we can detect amounts of genomic DNA of E. coli O157:H7 as low as a few CFU equivalents. Moreover, we have developed a new propidium monoazide (PMA)-real-time PCR protocol that allows for the clear differentiation of viable from dead cells. In addition, the protocol was adapted to a 96-well plate format for easy and consistent handling of a large number of samples. Amplification of DNA from PMA-treated dead cells was almost completely inhibited, in contrast to the virtually unaffected amplification of DNA from PMA-treated viable cells. With beef spiked simultaneously with 8 × 10(7) dead cells/g and 80 CFU viable cells/g, we were able to selectively detect viable E. coli O157:H7 cells with an 8-h enrichment. In conclusion, this PMA-real-time PCR assay offers a sensitive and specific means to selectively detect viable E. coli O157:H7 cells in spiked beef. It also has the potential for high-throughput selective detection of viable E. coli O157:H7 cells in other food matrices and, thus, will have an impact on the accurate microbiological and epidemiological monitoring of food safety and environmental sources.


Subject(s)
Escherichia coli O157/genetics , Food Safety/methods , Genetic Markers/genetics , Real-Time Polymerase Chain Reaction/methods , Azides , DNA Primers/genetics , Escherichia coli O157/growth & development , Open Reading Frames/genetics , Propidium/analogs & derivatives , Sensitivity and Specificity , Species Specificity , Stem Cells
11.
Biochim Biophys Acta ; 1793(10): 1540-70, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19559056

ABSTRACT

There has been increasing evidence pointing to the mitochondrial respiratory chain (MRC) as a novel and important target for the actions of 17beta-estradiol (E(2)) and estrogen receptors (ER) in a number of cell types and tissues that have high demands for mitochondrial energy metabolism. This novel E(2)-mediated mitochondrial pathway involves the cooperation of both nuclear and mitochondrial ERalpha and ERbeta and their co-activators on the coordinate regulation of both nuclear DNA- and mitochondrial DNA-encoded genes for MRC proteins. In this paper, we have: 1) comprehensively reviewed studies that reveal a novel role of estrogens and ERs in the regulation of MRC biogenesis; 2) discussed their physiological, pathological and pharmacological implications in the control of cell proliferation and apoptosis in relation to estrogen-mediated carcinogenesis, anti-cancer drug resistance in human breast cancer cells, neuroprotection for Alzheimer's disease and Parkinson's disease in brain, cardiovascular protection in human heart and their beneficial effects in lens physiology related to cataract in the eye; and 3) pointed out new research directions to address the key questions in this important and newly emerging area. We also suggest a novel conceptual approach that will contribute to innovative regimens for the prevention or treatment of a wide variety of medical complications based on E(2)/ER-mediated MRC biogenesis pathway.


Subject(s)
Electron Transport/drug effects , Electron Transport/physiology , Estrogens/physiology , Mitochondria/drug effects , Mitochondria/physiology , Receptors, Estrogen/physiology , Alzheimer Disease/drug therapy , Alzheimer Disease/etiology , Animals , Apoptosis/genetics , Apoptosis/physiology , Breast Neoplasms/drug therapy , Breast Neoplasms/etiology , Cardiovascular Diseases/prevention & control , Cell Proliferation , DNA, Mitochondrial/genetics , DNA, Mitochondrial/metabolism , Drug Resistance, Neoplasm , Electron Transport/genetics , Estradiol/pharmacology , Estradiol/physiology , Female , Genome, Mitochondrial , Humans , Lens, Crystalline/drug effects , Lens, Crystalline/physiology , Male , Mitochondria/genetics , Mitochondrial Proteins/physiology , Mitochondrial Proton-Translocating ATPases/physiology , Models, Biological , Neoplasms, Hormone-Dependent/drug therapy , Neoplasms, Hormone-Dependent/etiology , Neuroprotective Agents/pharmacology , Parkinson Disease/drug therapy , Parkinson Disease/etiology , Protein Biosynthesis/drug effects , Transcription, Genetic/drug effects
12.
Biochim Biophys Acta ; 1796(2): 162-75, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19527773

ABSTRACT

Triple negative breast cancer (TNBC) is a type of aggressive breast cancer lacking the expression of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor-2 (HER-2). TNBC patients account for approximately 15% of total breast cancer patients and are more prevalent among young African, African-American and Latino women patients. The currently available ER-targeted and Her-2-based therapies are not effective for treating TNBC. Recent studies have revealed a number of novel features of TNBC. In the present work, we comprehensively addressed these features and discussed potential therapeutic approaches based on these features for TNBC, with particular focus on: 1) the pathological features of TNBC/basal-like breast cancer; 2) E(2)/ERbeta-mediated signaling pathways; 3) G-protein coupling receptor-30/epithelial growth factor receptor (GPCR-30/EGFR) signaling pathway; 4) interactions of ERbeta with breast cancer 1/2 (BRCA1/2); 5) chemokine CXCL8 and related chemokines; 6) altered microRNA signatures and suppression of ERalpha expression/ERalpha-signaling by micro-RNAs; 7) altered expression of several pro-oncongenic and tumor suppressor proteins; and 8) genotoxic effects caused by oxidative estrogen metabolites. Gaining better insights into these molecular pathways in TNBC may lead to identification of novel biomarkers and targets for development of diagnostic and therapeutic approaches for prevention and treatment of TNBC.


Subject(s)
Breast Neoplasms/chemistry , Estrogen Receptor alpha/analysis , Receptor, ErbB-2/analysis , Receptors, Progesterone/analysis , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Cadherins/analysis , Chemokines, CXC/physiology , E-Selectin/analysis , ErbB Receptors/physiology , Estrogen Receptor beta/analysis , Estrogen Receptor beta/physiology , Estrogens/metabolism , Estrogens/toxicity , Female , Humans , MicroRNAs/physiology , Receptors, Notch/physiology , Signal Transduction
13.
Biochim Biophys Acta ; 1793(7): 1128-43, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19348861

ABSTRACT

The prevalence of obesity among children, adolescents and adults has been dramatically increasing worldwide during the last several decades. The obesity epidemic has been recognized as one of the major global health problems, because its health hazard is linked to a number of common diseases including breast and prostate cancers. Obesity is caused by combination of genetic and environmental factors. While genetic contribution to obesity has been known to be significant, the genetic factors remain relatively unchanged. Recent studies have highlighted the involvement of environmental "obesogens", i.e. the xenobiotic chemicals that can disrupt the normal development and homeostatic control over adipogenesis and energy balance. Several lines of evidence suggest that increasing exposure to chemicals with endocrine-disrupting activities (endocrine-disrupting chemicals, EDCs) contributes to the increased obesity. The cellular and molecular mechanisms underlying obesogen-associated obesity are just now being appreciated. In this paper, we comprehensively reviewed current knowledge about the role of estrogen receptors alpha and beta (ERalpha and ERbeta) in regulation of energy metabolism pathways, including glucose transport, glycolysis, tricarboxylic acid (TCA) cycle, mitochondrial respiratory chain (MRC), adenosine nucleotide translocator (ANT) and fatty acid beta-oxidation and synthesis, by estrogens; and then examined the disturbance of E(2)/ER-mediated energy metabolism pathways by environmental obesogens; and finally, we discussed the potential implications of disturbance of energy metabolism pathways by obesogens in obesity and pointed out several key aspects of this area that need to be further explored. A better understanding of the cellular and molecular mechanisms underlying obesogen-associated obesity will lead to new approaches for slow down and/or prevention of the increased trend of obesity associated with exposure to obesogens.


Subject(s)
Endocrine Disruptors/pharmacology , Energy Metabolism/drug effects , Estrogens/pharmacology , Obesity/etiology , Animals , Environmental Exposure , Estrogens/chemistry , Humans , Signal Transduction
14.
Adv Exp Med Biol ; 630: 1-18, 2008.
Article in English | MEDLINE | ID: mdl-18637481

ABSTRACT

CumuIative and excessive exposure to estrogens is associated with increased breast cancer risk. The traditional mechanism explaining this association is that estrogens affect the rate of cell division and apoptosis and thus manifest their effect on the risk of breast cancer by affecting the growth of breast epithelial tissues. Highly proliferative cells are susceptible to genetic errors during DNA replication. The action of estrogen metabolites offers a complementary genotoxic pathway mediated by the generation of reactive estrogen quinone metabolites that can form adducts with DNA and generate reactive oxygen species through redox cycling. In this chapter, we discussed a novel mitochondrial pathway mediated by estrogens and their cognate estrogen receptors (ERs) and its potential implications in estrogen-dependent carcinogenesis. Several lines of evidence are presented to show: (1) mitochondrial localization of ERs in human breast cancer cells and other cell types; (2) a functional role for the mitochondrial ERs in regulation of the mitochondrial respiratory chain (MRC) proteins and (3) potential implications of the mitochondrial ER-mediated pathway in stimulation of cell proliferation, inhibition of apoptosis and oxidative damage to mitochondrial DNA. The possible involvement of estrogens and ERs in deregulation of mitochondrial bioenergetics, an important hallmark of cancer cells, is also described. An evolutionary view is presented to suggest that persistent stimulation by estrogens through ER signaling pathways of MRC proteins and energy metabolic pathways leads to the alterations in mitochondrial bioenergetics and contributes to the development of estrogen-related cancers.


Subject(s)
Concept Formation , Hormones/physiology , Mitochondria/physiology , Neoplasms/etiology , Energy Metabolism/physiology , Estrogens/pharmacology , Humans , Mitochondria/metabolism , Models, Biological , Neoplasms/chemically induced , Neoplasms/metabolism , Neoplasms, Hormone-Dependent/metabolism , Receptors, Estrogen/physiology , Signal Transduction/physiology
15.
Biochim Biophys Acta ; 1773(12): 1732-46, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17604135

ABSTRACT

Both estrogen receptors (ER) alpha (ERalpha) and beta (ERbeta) are localized in the nucleus, plasma membrane, and mitochondria, where they mediate the different physiological effects of estrogens. It has been observed that the relative subcellular localization of ERs is altered in several cancer cells. We have demonstrated that MCF-10F cells, the immortal and non-tumorigenic human breast epithelial cells (HBEC) that are ERalpha-negative and ERbeta-positive, are transformed in vitro by 17beta-estradiol (E(2)), generating highly invasive cells that are tumorigenic in severe combined immunodeficient mice. E(2)-transformed MCF-10F (trMCF) cells exhibit progressive loss of ductulogenesis, invasive (bsMCF) and tumorigenic (caMCF) phenotypes. Immunolocalization of ERbeta by confocal fluorescent microscopy and electron microscopy revealed that ERbeta is predominantly localized in mitochondria of MCF-10F and trMCF cells. Silencing ERbeta expression with ERbeta-specific small interference RNA (siRNA-ERbeta) markedly diminishes both nuclear and mitochondrial ERbeta in MCF-10F cells. The ERbeta shifts from its predominant localization in the mitochondria of MCF-10F and trMCF cells to the nucleus of bsMCF cells, becoming predominantly nuclear in caMCF cells. Furthermore, we demonstrated that the mitochondrial ERbeta in MCF-10F cells is involved in E(2)-induced expression of mitochondrial DNA (mtDNA)-encoded respiratory chain (MRC) proteins. This is the first report of an association of changes in the subcellular localization of ERbeta with various stages of E(2)-induced transformation of HBEC and a functional role of mitochondrial ERbeta in mediating E(2)-induced MRC protein synthesis. Our findings provide a new insight into one of the potential roles of ERbeta in human breast cancer.


Subject(s)
Cell Nucleus/metabolism , Cell Transformation, Neoplastic/drug effects , Epithelial Cells/pathology , Estrogen Receptor beta/metabolism , Estrogens/pharmacology , Mitochondria/metabolism , Mitochondrial Proteins/biosynthesis , Animals , Breast/drug effects , Breast/pathology , Cell Line , Cell Nucleus/drug effects , Electron Transport/drug effects , Electron Transport Complex IV/metabolism , Epithelial Cells/drug effects , Female , Gene Silencing/drug effects , Humans , Mice , Mitochondria/drug effects , Mitochondria/enzymology , Mitochondria/ultrastructure , Nitriles/pharmacology , Propionates/pharmacology , Protein Transport/drug effects , Subcellular Fractions
16.
Front Biosci ; 11: 151-72, 2006 Jan 01.
Article in English | MEDLINE | ID: mdl-16146722

ABSTRACT

The breast attains its maximum development during pregnancy and lactation. After menopause the breast regresses in both nulliparous and parous women containing lobular structures that have been designated lobules type 1. Despite the similarity in the lobular composition of the breast at menopause, the fact that nulliparous women are at higher risk of developing breast cancer than parous women, indicates that Lobules type 1 in these two groups of women might be biologically different, or exhibit different susceptibility to carcinogenesis. Based on these observations it was postulated that the Lobule type 1 found in the breast of nulliparous women and of parous women with breast cancer never went through the process of differentiation, retaining a high concentration of epithelial cells that are targets for carcinogens and therefore susceptible to undergo neoplastic transformation, these cell are called Stem cells 1, whereas Lobules type 1 structures found in the breast of early parous postmenopausal women free of mammary pathology, on the other hand, are composed of an epithelial cell population that is refractory to transformation called Stem cells 2. It was further postulated that the degree of differentiation acquired through early pregnancy has changed the "genomic signature" that differentiates the Lobule type 1 from the early parous women from that of the nulliparous women by shifting the Stem cell 1 to a Stem cell 2 that is refractory to carcinogenesis, making this the postulated mechanism of protection conferred by early full term pregnancy. The identification of a putative breast stem cell (Stem cell 1) has reached in the last decade a significant impulse and several markers also reported for other tissues have been found in the mammary epithelial cells of both rodents and humans. Although still more work needs to be done in order to better understand the role of the Stem cell 2 and its interaction with the genes that confer it a specific signature, collectively, the data presently available provides evidence that pregnancy, through the process of cell differentiation, shifts the Stem cell 1 to Stem cell 2, cells that exhibit a specific genomic signature that could be responsible for the refractoriness of the mammary gland to carcinogenesis.


Subject(s)
Mammary Glands, Animal/pathology , Mammary Glands, Human/pathology , Neoplasms/metabolism , Stem Cells/metabolism , Animals , Breast Neoplasms/metabolism , Carcinoma, Ductal, Breast/pathology , Cell Differentiation , Cell Line, Tumor , Cell Transformation, Neoplastic , Epithelial Cells/metabolism , Estrogen Receptor alpha/biosynthesis , Estrogen Receptor beta/biosynthesis , Female , Gene Expression Regulation , Humans , Models, Biological , Pregnancy , RNA , Rats , Reverse Transcriptase Polymerase Chain Reaction , Time Factors
17.
Breast Cancer Res Treat ; 96(1): 1-15, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16322895

ABSTRACT

Prolonged exposure to 17beta-estradiol (E2) is a key etiological factor for human breast cancer. The biological effects and carcinogenic effects of E2 are mediated via estrogen receptors (ERs), ERalpha and ERbeta. Anti-estrogens, e.g. tamoxifen, and aromatase inhibitors have been used to treat ER-positive breast cancer. While anti-estrogen therapy is initially successful, a major problem is that most tumors develop resistance and the disease ultimately progresses, pointing to the need of developing alternative drugs targeting to other critical targets in breast cancer cells. We have identified that Na+, K+-ATPase, a plasma membrane ion pump, has unique/valuable properties that could be used as a potentially important target for breast cancer treatment: (a) it is a key player of cell adhesion and is involved in cancer progression; (b) it serves as a versatile signal transducer and is a target for a number of hormones including estrogens and (d) its aberrant expression and activity are implicated in the development and progression of breast cancer. There are several lines of evidence indicating that ouabain and related digitalis (the potent inhibitors of Na+, K+-ATPase) possess potent anti-breast cancer activity. While it is not clear how the suggested anti-cancer activity of these drugs work, several observations point to ouabain and digitalis as being potential ER antagonists. We critically reviewed many lines of evidence and postulated a novel concept that Na+, K+-ATPase in combination with ERs could be important targets of anti-breast cancer drugs. Modulators, e.g. ouabain and related digitalis could be useful to develop valuable anti-breast cancer drugs as both Na+, K+-ATPase inhibitors and ER antagonists.


Subject(s)
Breast Neoplasms/drug therapy , Digitalis Glycosides/pharmacology , Enzyme Inhibitors/pharmacology , Ouabain/pharmacology , Receptors, Estrogen/antagonists & inhibitors , Sodium-Potassium-Exchanging ATPase/antagonists & inhibitors , Animals , Breast Neoplasms/enzymology , Humans , Models, Biological , Sodium-Potassium-Exchanging ATPase/metabolism
18.
Biochim Biophys Acta ; 1746(1): 1-17, 2005 Oct 30.
Article in English | MEDLINE | ID: mdl-16169101

ABSTRACT

It is well known that the biological and carcinogenic effects of 17beta-estradiol (E2) are mediated via nuclear estrogen receptors (ERs) by regulating nuclear gene expression. Several rapid, non-nuclear genomic effects of E2 are mediated via plasma membrane-bound ERs. In addition, there is accumulating evidence suggesting that mitochondria are also important targets for the action of estrogens and ERs. This review summarized the studies on the effects of estrogens via ERs on mitochondrial structure and function. The potential physiological and pathophysiological implications of deficiency and/or overabundance of these E2/ER-mediated mitochondrial effects in stimulation of cell proliferation, inhibition of apoptosis, E2-mediated cardiovascular and neuroprotective effects in target cells are also discussed.


Subject(s)
Electron Transport/physiology , Estrogens/metabolism , Mitochondria/chemistry , Mitochondria/metabolism , Receptors, Estrogen/metabolism , Animals , DNA, Mitochondrial/genetics , Gene Expression Regulation , Humans , Mitochondria/genetics
19.
Ann N Y Acad Sci ; 1028: 258-72, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15650251

ABSTRACT

Estrogen receptor (ER)alpha and ERbeta are localized in the nucleus and involved in the regulation of nuclear estrogen-responsive genes by 17beta estradiol (E2). In addition, recently others have shown that upon E2 binding, ERalpha localizes to the plasma membrane and initiates mitogen-activated protein kinase (MAPK)-mediated signal transduction. Previously, we reported that in liver, cultured rat hepatocytes and human HepG2 cells, estrogen treatment enhanced mitochondrial DNA (mtDNA)-encoded gene transcript levels. These effects were blocked by a specific antiestrogen, suggesting a role for the ER. Others have reported the presence of putative estrogen-responsive elements in mtDNA. These observations suggested the hypothesis that the ER localized in mitochondria and functioned directly to enhance the levels of mtDNA-encoded transcripts, analogous to what has been observed for the glucocorticoid hormone receptor. Using Western blot analysis, confocal immunofluorescence, immunogold electron microscopy, and gel electrophoresis mobility shift assays, we have demonstrated the estrogen-dependent presence of ERbeta and ERalpha within mitochondria of HepG2 and MCF-7 human breast tumor cells. Together, these results suggest that the ERs may act as transcription factors directly involved in the regulation by E2 of mtDNA transcription.


Subject(s)
Estrogens/metabolism , Gene Expression Regulation, Neoplastic , Mitochondria/metabolism , Neoplasms/metabolism , Animals , Apoptosis , Blotting, Western , Cell Line, Tumor , Cells, Cultured , DNA, Mitochondrial/metabolism , Dose-Response Relationship, Drug , Humans , Immunohistochemistry , MAP Kinase Signaling System , Microscopy, Confocal , Mitochondria/pathology , Promoter Regions, Genetic , Rats , Receptors, Estrogen/metabolism , Signal Transduction , Time Factors , Transcription, Genetic
20.
Toxicol Sci ; 75(2): 271-8, 2003 Oct.
Article in English | MEDLINE | ID: mdl-12857939

ABSTRACT

Ethinyl estradiol (EE) is a strong promoter and weak hepatocarcinogen in rats. Previously, we demonstrated that EE enhanced the transcript levels of nuclear genome- and mitochondrial genome-encoded genes and respiratory chain activity in female rat liver, and also inhibited transforming growth factor beta (TGFbeta)-induced apoptosis in cultured liver slices and hepatocytes from female rats. In this study, using cultured female rat hepatocytes, we observed that EE, within 24 h, increased the transcript levels of the mitochondrial genome-encoded genes cytochrome oxidase subunits I, II, and III. This effect was accompanied by increased mitochondrial respiratory chain activity, as reflected by increased mitochondrial superoxide generation, and detected by lucigenin-derived chemiluminescence and cellular ATP levels. EE also enhanced the levels of Bcl-2 protein. Biochemical analyses indicated that EE significantly increased both the levels of glutathione (reduced [GSH] and oxidized [GSSG] forms) per mg protein in mitochondria and nuclei, while the percentage of total glutathione in the oxidized form was not affected. This finding was supported by confocal microscopy. These effects caused by EE may contribute, at least in part, to the EE-mediated inhibition of hepatic apoptosis.


Subject(s)
Adenosine Triphosphate/metabolism , DNA, Mitochondrial/drug effects , Estrogens/toxicity , Ethinyl Estradiol/toxicity , Glutathione/metabolism , Hepatocytes/drug effects , Proto-Oncogene Proteins c-bcl-2/metabolism , Animals , DNA, Complementary/metabolism , DNA, Mitochondrial/genetics , DNA, Mitochondrial/metabolism , Dose-Response Relationship, Drug , Electron Transport/drug effects , Electron Transport/genetics , Electron Transport Complex IV/metabolism , Female , Gene Expression/drug effects , Hepatocytes/metabolism , Mitochondria, Liver/drug effects , Mitochondria, Liver/metabolism , RNA, Messenger/metabolism , Rats , Rats, Inbred F344 , Superoxides/metabolism , Transcription, Genetic/drug effects , Transcription, Genetic/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...